Sanofi’s tolebrutinib gets CHMP backing for certain MS patients despite FDA rejection

April 24, 2026 07:30 AM EDTUpdated 11:09 AM Pharma Sanofi’s tole­bru­ti­nib gets CHMP back­ing for cer­tain MS pa­tients de­spite FDA re­jec­tion Ayisha Sharma News Reporter Sanofi’s tole­bru­ti­nib is on track to get an ap­proval in Eu­rope for a type of mul­ti­ple scle­ro­sis even af­ter re­ceiv­ing a com­plete re­sponse let­ter from … Sign up to read this article for free. Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox. SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER